Drug intelligence / Profile preview

glycerol + heparin

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Intravenous, Subcutaneous
01

Overview

Glycerol + heparin is a combination of two agents with distinct mechanisms and clinical uses. Glycerol (also known as glycerin) is a hyperosmolar agent primarily used to reduce cerebral edema in acute stroke and other conditions by drawing water out of tissues, thereby decreasing intracranial pressure[2]. Heparin is an anticoagulant that potentiates the activity of antithrombin III, inhibiting thrombin and factor Xa to prevent clot formation[3][4][6]. This combination does not represent a standard fixed-dose pharmaceutical product but may be co-administered in certain clinical scenarios where both reduction of edema (glycerol) and prevention or treatment of thrombosis (heparin) are desired. Notably, there is evidence that intravenous nitroglycerin (glyceryl trinitrate), which shares structural similarity with glycerol but has different pharmacology, can reduce the anticoagulant effect of heparin when administered together; however, direct interaction data for plain glycerol plus heparin are limited[1][5][7][9].

Other names
glycerin + heparinglyceryl + heparin
02

Targets

F10 (Factor Xa)ATIII (Antithrombin III)F2 (Thrombin)

Beyond the preview

Go deeper on glycerol + heparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glycerol + heparin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call